论文部分内容阅读
目的探讨曲美他嗪对缺血性心肌病(ICM)患者的T波峰末间期(Tpe)的影响。方法 ICM患者120例,随机分为曲美他嗪(A组,61例)和常规治疗(B组,59例)两组,观察其在第2、4、6、8、10、12个月的Tpe的变化。结果 A组治疗4个月后Tpe值明显小于治疗前[(131.36±14.67)ms vs.(137.03±17.17)ms](P<0.05);而B组在治疗10个月后Tpe才明显缩短[(127.64±12.62)ms vs.(135.98±18.56)ms](P<0.05)。结论 ICM患者在常规治疗基础上加用曲美他嗪可以更有效地缩短Tpe。
Objective To investigate the effect of trimetazidine on T-peak (Tpe) in patients with ischemic cardiomyopathy (ICM). Methods One hundred and twenty ICM patients were randomly divided into trimetazidine group (A group, 61 cases) and conventional treatment group (B group, 59 cases). Two groups were observed on the 2nd, 4th, 6th, 8th, Tpe changes. Results The Tpe of group A after 4 months treatment was significantly lower than that before treatment [(131.36 ± 14.67) ms vs. (137.03 ± 17.17) ms] (P <0.05) (127.64 ± 12.62) ms vs. (135.98 ± 18.56) ms] (P <0.05). Conclusion ICM patients with trimetazidine combined with conventional therapy can be more effective in shortening Tpe.